Olodaterol hydrochloride is a long-acting β2-adrenergic receptor agonist (LABA) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. It provides sustained bronchodilation for up to 24 hours, allowing once-daily dosing, which improves patient adherence. It is not indicated for the relief of acute bronchospasm or as monotherapy for asthma. Clinical studies have demonstrated that olodaterol significantly improves lung function (as measured by FEV1), reduces symptoms, enhances health-related quality of life, and decreases the need for rescue medication in patients with COPD. It may also exert anti-inflammatory effects in COPD by modulating TGF-mediated neutrophilic inflammation.